Trials / Completed
CompletedNCT06049329
A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity
Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Doses of Oral NNC0487-0111 in Japanese Participants With Obesity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as an oral tablet to Japanese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NNC0487-0111 | Participants will get one tablet to swallow at the same time of the day. |
| DRUG | Placebo (NNC0487-0111) | Participants will get one tablet to swallow at the same time of the day. |
Timeline
- Start date
- 2023-09-14
- Primary completion
- 2023-12-15
- Completion
- 2023-12-15
- First posted
- 2023-09-22
- Last updated
- 2025-03-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT06049329. Inclusion in this directory is not an endorsement.